BioCentury | Mar 24, 2020
Deals

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

...its immuno-oncology quiver. Since November 2018, the Japanese pharma has acquired CAR T platform developer Xyphos Biosciences Inc....
...gilteritinib for acute myelogenous leukemia and antibody-drug conjugate Padcev enfortumab vedotin-ejfv for bladder cancer (see “Xyphos...
BioCentury | Dec 27, 2019
Company News

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

...front for Xyphos Biosciences Inc., and the biotech’s shareholders are eligible for $545 million in milestones. With Xyphos’...
...top, we climbed every rung a deal must go up.” James Knighton, Xyphos According to Xyphos...
...also be used to treat HIV (see “Gladstone, Xyphos Target CARs to Latent HIV” ). Xyphos’...
BioCentury | Oct 25, 2019
Tools & Techniques

Gladstone, Xyphos target universal CARs to latent HIV

...too costly, he said. In a Cell paper published on Thursday, the team described deploying Xyphos’...
...convertible CAR platform to improve the safety of anti-HIV CAR Ts and prevent viral escape. Xyphos...
...T target requires altering only the MicAbody antigen-binding end (see “Avidly Specific” ). Greene and Xyphos...
BioCentury | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

...company RefleXion Medical Inc. (Hayward, Calif.) hired Thorsten Melcher as CBO. He was CBO at Xyphos Biosciences Inc....
BioCentury | Oct 19, 2018
Company News

Xyphos, Parker Institute steer next-gen Car T therapies into solid tumors

...the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos...
...research will focus primarily on treating solid tumors, which traditional CAR Ts have difficulty entering. Xyphos...
...They will evaluate the partnered therapies against known, undisclosed cancer cell surface targets, Knighton said. Xyphos...
BioCentury | Oct 18, 2018
Company News

Xyphos, Parker Institute steer next-gen CAR T therapies into solid tumors

...the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos...
...research will focus primarily on treating solid tumors, which traditional CAR Ts have difficulty entering. Xyphos...
...They will evaluate the partnered therapies against known, undisclosed cancer cell surface targets, Knighton said. Xyphos...
BioCentury | Jul 3, 2018
Company News

Management tracks: Cigna, Novocure, Voyager

...Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506). Modular CAR T cell company Xyphos...
BioCentury | Dec 8, 2017
Company News

AvidBiotics splits in two

...Corp (South San Francisco, Calif.) said it will split into two separate entities. One company, Xyphos...
...using its Avidocin technology. Both companies will be located initially in South San Francisco, Calif. Xyphos'...
...AvidBiotics Corp., South San Francisco, Calif. Business: Cancer, infectious disease Elizabeth S. Eaton AvidBiotics Corp. Pylum Biosciences Inc. Xyphos...
Items per page:
1 - 8 of 8
BioCentury | Mar 24, 2020
Deals

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

...its immuno-oncology quiver. Since November 2018, the Japanese pharma has acquired CAR T platform developer Xyphos Biosciences Inc....
...gilteritinib for acute myelogenous leukemia and antibody-drug conjugate Padcev enfortumab vedotin-ejfv for bladder cancer (see “Xyphos...
BioCentury | Dec 27, 2019
Company News

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

...front for Xyphos Biosciences Inc., and the biotech’s shareholders are eligible for $545 million in milestones. With Xyphos’...
...top, we climbed every rung a deal must go up.” James Knighton, Xyphos According to Xyphos...
...also be used to treat HIV (see “Gladstone, Xyphos Target CARs to Latent HIV” ). Xyphos’...
BioCentury | Oct 25, 2019
Tools & Techniques

Gladstone, Xyphos target universal CARs to latent HIV

...too costly, he said. In a Cell paper published on Thursday, the team described deploying Xyphos’...
...convertible CAR platform to improve the safety of anti-HIV CAR Ts and prevent viral escape. Xyphos...
...T target requires altering only the MicAbody antigen-binding end (see “Avidly Specific” ). Greene and Xyphos...
BioCentury | Jul 19, 2019
Company News

Management tracks: Iovance, ViiV, Hercules, Pappas and more

...company RefleXion Medical Inc. (Hayward, Calif.) hired Thorsten Melcher as CBO. He was CBO at Xyphos Biosciences Inc....
BioCentury | Oct 19, 2018
Company News

Xyphos, Parker Institute steer next-gen Car T therapies into solid tumors

...the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos...
...research will focus primarily on treating solid tumors, which traditional CAR Ts have difficulty entering. Xyphos...
...They will evaluate the partnered therapies against known, undisclosed cancer cell surface targets, Knighton said. Xyphos...
BioCentury | Oct 18, 2018
Company News

Xyphos, Parker Institute steer next-gen CAR T therapies into solid tumors

...the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos...
...research will focus primarily on treating solid tumors, which traditional CAR Ts have difficulty entering. Xyphos...
...They will evaluate the partnered therapies against known, undisclosed cancer cell surface targets, Knighton said. Xyphos...
BioCentury | Jul 3, 2018
Company News

Management tracks: Cigna, Novocure, Voyager

...Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506). Modular CAR T cell company Xyphos...
BioCentury | Dec 8, 2017
Company News

AvidBiotics splits in two

...Corp (South San Francisco, Calif.) said it will split into two separate entities. One company, Xyphos...
...using its Avidocin technology. Both companies will be located initially in South San Francisco, Calif. Xyphos'...
...AvidBiotics Corp., South San Francisco, Calif. Business: Cancer, infectious disease Elizabeth S. Eaton AvidBiotics Corp. Pylum Biosciences Inc. Xyphos...
Items per page:
1 - 8 of 8